An Emollient Plus Balm Is Useful for the Management of Xerosis in Cancer Patients: A Real-World, Prospective, Observational, Multicenter Study

In a real-world, prospective, observational, multicenter study involving 319 cancer patients with xerosis, the use of an emollient PLUS balm containing Aquaphilus dolomiae extract (ADE-G1) significantly reduced the severity of xerosis. After approximately 4 weeks of daily application, 62.7% of patients experienced a reduction in xerosis severity, with a 67.7% decrease in objective clinical signs and a 57.4% decrease in subjective clinical signs (p < 0.0001 for both). Quality of life, as measured by the Dermatology Life Quality Index (DLQI), improved by 56.6% (p < 0.0001). Over 80% of patients were rated by physicians as having "effective" or "very effective" outcomes, and overall clinical success was achieved in 73.7% of patients. The balm was well-tolerated across different types of anticancer therapies, with a trend toward higher effectiveness in patients undergoing hormonotherapy.